NextCure skyrockets on Avere reverse-merger deal and $320 million financing plan

By: Quiver PriceTracker

Posted: 1 day, 11 hours ago / July 14, 2026 2:51 p.m. UTC

NXTC

NextCure, Inc. (NXTC) is up 211.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The biggest apparent catalyst is NextCure’s announcement of an all-stock merger with private biotech Avere Therapeutics alongside a concurrent $320 million private financing for the combined company. The move likely reflects investor enthusiasm for the new asset package, the large capital raise, and the company’s shift from its prior standalone oncology story into a better-funded reverse-merger transaction.

Details:

NextCure announced a proposed merger with Avere Therapeutics, and the combined company is expected to operate as Avere Therapeutics and trade under the symbol AVRX after closing.

The transaction includes a $320 million private investment intended to fund development of AVR-001, an oral once-weekly IL-23 therapy candidate.

Under the merger terms, pre-merger NextCure stockholders are expected to own about 1.21% of the combined company, showing that the market is valuing the incoming business and financing package rather than the legacy company alone.

Before this deal, NextCure had disclosed that its cash resources were limited and that additional capital would be needed to support operations beyond the first half of 2027, so the financing component may have meaningfully changed investor expectations.

Sources:

NextCure, SEC, Axios

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive NXTC Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$NXTC Hedge Fund Activity

We have seen 8 institutional investors add shares of $NXTC stock to their portfolio, and 7 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

OPALEYE MANAGEMENT INC. added 141,181 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,507,813
EXOME ASSET MANAGEMENT LLC removed 49,500 shares (-30.0%) from their portfolio in Q1 2026, for an estimated $528,660
VERDAD ADVISERS, LP added 42,955 shares (+inf%) to their portfolio in Q1 2026, for an estimated $458,759
SQUADRON CAPITAL MANAGEMENT LLC added 28,034 shares (+11.8%) to their portfolio in Q1 2026, for an estimated $299,403
WOODLINE PARTNERS LP added 27,498 shares (+inf%) to their portfolio in Q1 2026, for an estimated $293,678
RENAISSANCE TECHNOLOGIES LLC added 26,900 shares (+80.0%) to their portfolio in Q1 2026, for an estimated $287,292
CITADEL ADVISORS LLC added 15,292 shares (+inf%) to their portfolio in Q1 2026, for an estimated $163,318

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.